Cytokinetics To Present Late Breaking Science At ESC Congress, Including Phase 3 ACACIA‑HCM Results

Cytokinetics, Incorporated

Cytokinetics, Incorporated

CYTK

0.00

Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

Company to Host In-Person and Virtual Investor Event to Discuss Results from Late-Breaking Science Presentations

SOUTH SAN FRANCISCO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced three Late Breaking Science abstracts were accepted for presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany, including a Hot Line presentation of the primary results from ACACIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (HCM).

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.